Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30941091 | 0.86 | CCNE2 (0.40) | CCNE2CCNE1CDK2PDE2AHRH4 | |
| SCHEMBL25048280 | 0.85 | — | — | |
| SCHEMBL30941371 | 0.83 | CCNE2 (0.40) | CCNE2CCNE1CDK2PDE2AHRH4 | |
| SCHEMBL30941418 | 0.81 | CCNE2 (0.37) | CCNE2CCNE1CDK2PDE2AHRH4 | |
| SCHEMBL30941531 | 0.81 | CCNE2 (0.35) | CCNE2CCNE1CDK2HRH4LMNA | |
| SCHEMBL30941332 | 0.81 | ACP1 (0.37) | CCNE2CCNE1CDK2HRH4MAPT | |
| SCHEMBL25049210 | 0.81 | SLC6A4 (0.33) | CCNE2CCNE1CDK2MAPT | |
| SCHEMBL31618002 | 0.80 | CCNE2 (0.36) | CCNE2CCNE1CDK2PDE2ABCDIN3D | |
| SCHEMBL30940862 | 0.80 | CCNE2 (0.36) | CCNE2CCNE1CDK2PDE2ABCDIN3D | |
| SCHEMBL25047646 | 0.79 | KDM1A (0.33) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | CCNE2 2226/4885CCNE1 1364/4885CDK2 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.